Tjeerd Barf
30Patents
5h-index
57Co-inventors
72Inventor score
Filing activity: Aug 24, 1998 → Aug 16, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9290504B2 | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors | Emerging Cross-Sectional Technologies | 23 | Active |
| US6410585B1 | Inhibitors of protein tyrosine phosphatase | Chemistry; Metallurgy | 12 | Expired |
| US10272083B2 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | Chemistry; Metallurgy | 8 | Active |
| US9758524B2 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | Emerging Cross-Sectional Technologies | 7 | Active |
| US9718828B2 | BTK Inhibitors | Chemistry; Metallurgy | 6 | Active |
| US9790226B2 | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as BtK inhibitors | Emerging Cross-Sectional Technologies | 5 | Active |
| US9796721B2 | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide | Chemistry; Metallurgy | 5 | Active |
| US11771696B2 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | Chemistry; Metallurgy | 3 | Active |
| US10239883B2 | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors | Emerging Cross-Sectional Technologies | 3 | Active |
| US9949971B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor | Chemistry; Metallurgy | 3 | Active |
| US6353023B1 | Inhibitors of protein tyrosine phosphatase | Chemistry; Metallurgy | 2 | Expired |
| US11090302B2 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | Chemistry; Metallurgy | 2 | Active |
| US11654143B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | Human Necessities | 2 | Active |
| US10328080B2 | Therapeutic combination of PI3K inhibitor and a BTK inhibitor | Human Necessities | 2 | Active |
| US10736893B2 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | Chemistry; Metallurgy | 1 | Active |
| US11166951B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | Human Necessities | 1 | Active |
| US7030135B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | Chemistry; Metallurgy | 1 | Expired |
| US11110088B2 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | Chemistry; Metallurgy | 1 | Active |
| US9102676B2 | MK2 inhibitors | Emerging Cross-Sectional Technologies | 0 | Active |
| US11059829B2 | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate | Chemistry; Metallurgy | 0 | Active |
| US10934296B2 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | Emerging Cross-Sectional Technologies | 0 | Active |
| US7125900B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | Chemistry; Metallurgy | 0 | Expired |
| US11820777B2 | Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide | Chemistry; Metallurgy | 0 | Active |
| US7618961B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | Chemistry; Metallurgy | 0 | Expired |
| US7671051B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.